Jeff Aronin is chairman and CEO of Paragon Biosciences and has been since 2010. Paragon is a global healthcare and biopharmaceutical Investment Company with several portfolio companies like Castle Creek and Harmony Bioscience. Aronin has served as a non-executive chairman for both. As Aronin’s own webpage says, (https://www.jeffaronin.com/) he has “nearly 20 years of experience developing global biotech and healthcare innovation companies. His expertise in complex science, rare diseases, and drug development has made him one of the most successful and innovative leaders in the bioscience sector”.
After graduating from Northern Illinois University and obtaining an MBA from DePaul University, Jeff Aronin had work experience in healthcare before following his own path as an entrepreneur, creating Ovation Pharmaceuticals LLC and serving as its CEO from 2000 to 2009. Ovation was created because Aronin knew a different focus was necessary in the pharmaceutical world: someone needed to do more for patients with rare and untreatable diseases.
Jeff is passionate about helping people and expanding knowledge in the industry, that’s why he always tries to bring up amazing teams of scientists and businessmen to research new, cheaper and more effective drug treatments and therapies. He and his collaborators have an incredible track record of bringing innovation to the pharmaceutical market to improve and save the life of unnoticed patients. His teams have got 13 Novel Drug Approvals through the FDA, proof of his success in the sector. Aronin has been successful in developing several biotechnology companies in the Paragon portfolio such as Castle Creek and Harmony Biosciences, serving in both as non-executive chairman. Castle Creek specializes in uncommon genetic dermatology diseases like epidermolysis bullosa simplex. Harmony Biosciences is dedicated to central nervous system ailments like narcolepsy and cataplexy.
All the way through his career, Jeff Aronin has obtained several honors and awards for his dedication to the industry and his focus on helping often overlooked patients such as: the 2017 Weizmann Leadership Award, Brain Research Foundation; Buyouts magazine “Deal of the Year” 2010, Ovation Pharmaceuticals; Scrip Award “Pharma Company of the Year-Small and Medium-sized Enterprises,” 2006 & 2007, Ovation Pharmaceuticals; and a host of other notable acknowledgments.